WSNAF (WSNAF) Stock Price & Analysis
WSNAF (WSNAF) rose 0.00% to USD 0 as of July 25, 2026 at 14:22 UTC, according to Nexqual real-time market data.
WSNAF last closed at USD 0; the session ranged USD 0.01–0.02 on volume of 15,923 shares. Market capitalization is $121,549, with a 52-week range of USD 0–0.06 (PNK). Source: Nexqual, July 25, 2026 at 14:22 UTC.
Key Statistics (as of July 25, 2026 at 14:22 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0.01 |
| Day Range | USD 0.01 – 0.02 |
| 52-Week Range | USD 0 – 0.06 |
| Volume | 15,923 shares |
| Market Cap | $121,549 |
| Exchange | PNK |
Technical Analysis (WSNAF)
Nexqual's technical model rates WSNAF "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 14:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 0 (oversold) |
| vs SMA50 | Below (USD 0.01) |
| MACD | -0 (negative) |
Analyst Ratings (WSNAF)
Wall Street analysts rate WSNAF "None", per Nexqual as of July 25, 2026 at 14:22 UTC.
| Consensus Rating | None |
|---|
Earnings (WSNAF)
Source: Nexqual, July 25, 2026 at 14:22 UTC.
Financials & Fundamentals (WSNAF)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.11 |
| Total Cash | $46,929 |
| Total Debt | $250,000 |
| Free Cash Flow | $582,157 |
Source: Nexqual, July 25, 2026 at 14:22 UTC.
Financial Health Score (WSNAF)
Nexqual rates WSNAF's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 14:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $47K cash, no debt |
| Cash Flow | Strong — FCF $582K, 218% margin |
| Efficiency | Mixed — No data |
Ownership (WSNAF)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.11% |
| Shares Outstanding | 20.92M |
| Float | 20.49M |
Source: Nexqual, July 25, 2026 at 14:22 UTC.
Leadership (WSNAF)
WSNAF is led by Daniel Carcillo (age 40), Co-Founder, CEO & Chairman, per Nexqual as of July 25, 2026 at 14:22 UTC.
| Co-Founder, CEO & Chairman | Daniel Carcillo (age 40) |
|---|---|
| Chief Scientific Officer | Mark A. Wingertzahn (age 53) |
| Vice President of Investor Relations & Corporate Development | Keenan Gentry |
| Vice President of Communications | Izzy Forman |
| Senior Vice President of Medical & Scientific Affairs | Jeffrey T. Jewell |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALID | Allied Corp. | USD 0 | ▲ 0% |
| BETRF | BETTERLIFE PHARMA INC. | USD 0.15 | ▼ 13.45% |
| MYCOF | MYDECINE INNOVATIONS GROUP INC | USD 0.8 | ▲ 0% |
| VGGIF | Boosh Plant-Based Brands Inc. | USD 0 | ▲ 0% |
| HAVLF | HAVN LIFE SCIENCES INC. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 14:22 UTC. This page is informational and not investment advice.